Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy

Beijers, A.J.M.; Mols, Floortje; Dercksen, Wouter; Driessen, Chantal; Vreugdenhil, Gerard

doi:10.12788/jcso.0086

Cited by 78 publications

(60 citation statements)

References 27 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous research has linked CIPN-sx with poorer quality of life and decreased ability to function [28], but this is one of the first studies to address the question of whether CIPN-sx impact work in BCS post-treatment [28]. Results of this study add to the growing evidence showing the persistence of CIPN-sx after treatment [25, 26, 36], and extend these findings to the context of occupational function, demonstrating a clear link between the presence, frequency, number, and severity of CIPN-sx and BCS’ self-reported inability to work following treatment. Results of our analysis also suggest that (1) the total number of CIPN-sx Ctx+ report, regardless of their severity, may be a useful predictor of difficulty working and that (2) painful and non-painful CIPN-sx affecting the hands or feet (with or without treatment-related hearing deficits) may predict work difficulty for Ctx+ 1 M post-treatment.…”

Section: Discussionmentioning

confidence: 80%

“…There is growing evidence that CIPN-sx pose a risk to BCS not only during cancer treatment but after as well [24–26, 36–41]. Previous research has linked CIPN-sx with poorer quality of life and decreased ability to function [28], but this is one of the first studies to address the question of whether CIPN-sx impact work in BCS post-treatment [28].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment

Zanville

Nudelman

Smith

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

PurposeTo describe the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on breast cancer survivors’ (BCS) perceived ability to work post-treatment.MethodsThe sample included 22 chemotherapy-treated (Ctx+) and 22 chemotherapy-naïve (Ctx−) female BCS. Data was collected at the following three time points: baseline (post-surgery, pre-chemotherapy), 1 month (1 M) post-chemotherapy, and approximately 1 year (1 Y) later. The presence, frequency, number, and severity of CIPN-sx were self-reported using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity questionnaire (FACT/GOG-Ntx) version 4, a validated 11-item CIPN measure. Perceived ability to work was measured using an item from the Functional Well-Being subscale of the FACT/GOG-Ntx.ResultsAt 1 Y, more than 50 % of Ctx+ reported discomfort, numbness, or tingling in their hands or feet; weakness; or difficulty feeling small objects. The presence, number, and severity of these symptoms were correlated with being less able to work for Ctx+ at 1 M but not 1 Y. Results of a regression analysis using CIPN-sx to predict work ability found that models combining (1) hand numbness and trouble feeling small objects, (2) trouble buttoning buttons and trouble feeling small objects, (3) foot numbness and foot pain, (4) foot numbness and trouble walking, and (5) trouble hearing and hand pain each predicted survivors who were “not at all” able to work at 1 M.ConclusionsUnresolved CIPN-sx may play a role in challenges working for BCS post-treatment. These findings highlight the need for research to explore the impact that CIPN-sx have on BCS’ ability to work, as well as the development of interventions to improve work function in BCS with CIPN-sx.

show abstract

Section: Discussionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment

Zanville

Nudelman

Smith

et al. 2016

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…2 Falls share overlapping causes with functional declines and are another significant concern for cancer survivors. The risk of falls increases after a cancer diagnosis when compared with prediagnosis fall rates, 3 and fall rate in cancer survivors can be twice that of cancer-free peers 4 or communitydwelling older adults. 5 A persistent cancer treatment-related symptom that may influence physical function, fall risk, and quality of life (QOL) is chemotherapy-induced peripheral neuropathy (CIPN).…”

Section: Introductionmentioning

confidence: 99%

“…Neuropathies develop from nerve damage caused by cytotoxic chemotherapies and result in motor and sensory impairments and symptoms of sensory loss in hands and feet, burning, tingling, and pain. 5 CIPN may occur in up to 90% of patients during chemotherapy 4 and can persist in a proportion of survivors in the long term. 6,7 CIPN is consistently associated with lower self-report physical function and QOL during or after chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy

Winters-Stone

Horak

Jacobs

et al. 2017

JCO

275

211

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) may persist after treatment ends and may lead to functional decline and falls. This study compared objective and self-report measures of physical function, gait patterns, and falls between women cancer survivors with and without symptoms of CIPN to identify targets for functional rehabilitation. MethodsA secondary data analysis of 512 women cancer survivors (age, 62 6 6 years; time since diagnosis, 5.8 6 4.1 years) categorized and compared women self-reporting symptoms of CIPN (CIPN+) with asymptomatic women (CIPN2) on the following: maximal leg strength, timed chair stand, physical function battery, gait characteristics (speed; step number, rate, and length; base of support), selfreport physical function and disability, and falls in the past year. ResultsAfter an average of 6 years after treatment, 47% of women still reported symptoms of CIPN. CIPN+ had significantly worse self-report and objectively measured function than did CIPN2, with the exception of maximal leg strength and base of support during a usual walk. Gait was slower among CIPN+, with those women taking significantly more, but slower and shorter, steps than did CIPN2 (all P , .05). CIPN+ reported significantly more disability and 1.8 times the risk of falls compared with CIPN2 (P , .0001). Increasing symptom severity was linearly associated with worsening function, increasing disability, and higher fall risk (all P , .05). ConclusionThis work makes a significant contribution toward understanding the functional impact of CIPN symptoms on cancer survivors. Remarkably, 47% of women in our sample had CIPN symptoms many years after treatment, together with worse function, greater disability, and more falls. CIPN must be assessed earlier in the clinical pathway, and strategies to limit symptom progression and to improve function must be included in clinical and survivorship care plans.J Clin Oncol 35.

show abstract

“…Chronic painful CIPN is characterized by burning/shooting pain, numbness, and tingling in the hands and feet that can persist months to years following the completion of neurotoxic chemotherapy and may negatively affect quality of life and/or physical function (Beijers, Mols, Dercksen, Driessen, & Vreugdenhil, 2014;Smith et al, 2014).…”

mentioning

confidence: 99%

Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention

Knoerl

Barton

Holden

et al. 2018

CONJ

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy

Abstract: After a median follow-up of 6.5 months after cessation of therapy with oxaliplatin or taxanes, CIPN is common and leads to impairment in patient QoL. More research is needed to assess the impact of neurotoxicity on QoL.

Cited by 78 publications

References 27 publications

Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment

Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment

Falls, Functioning, and Disability Among Women With Persistent Symptoms of Chemotherapy-Induced Peripheral Neuropathy

Potential mediators of improvement in painful chemotherapy-induced peripheral neuropathy via a web-based cognitive behavioural intervention

Contact Info

Product

Resources

About